Global update on defining and treating high-risk localized prostate cancer with leuprorelin: A European perspective

BJU International

Volumn 99, Issue SUPPL. 1, 2007, Pages 2-5

  Boccon Gibod, Laurent ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Europe; High risk; Hormone therapy; Leuprorelin; Prostate cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ANDROGEN SUPPRESSION THERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG INTERMITTENT THERAPY; EUROPE; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PATHOLOGY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; RISK FACTOR; RISK REDUCTION; THERAPY DELAY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; EUROPE; HUMANS; LEUPROLIDE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 33845619103     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06591.x     Document Type: Conference Paper

References (12)

1. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
2. Stephenson AJ, Scardino PT, Eastham JA et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98: 715-7
3. D'Amico AV, Whittington R, Malkowicz SB et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999; 17: 168-72
4. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56
5. Collette L, Studer U, Whelan P et al. Is the degree of PSA decline after immediate androgen deprivation a prognostic factor for outcome in patients with T0-4, N0, M0 prostate cancer not suitable for local treatment with curative intent? (results from the EORTC 30891 trial). European Association of Urology Annual Meeting 2006: Abstract 1062
6. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8
7. Iversen P, Johansson JE, Lodding P et al. Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 2004; 172: 1871-6
8. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with nodepositive prostate cancer. N Engl J Med 1999; 341: 1781-8
9. ASTRO. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37: 1035-41
10. Moul JW, Wu H, Sun L et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141-7
11. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-83
12. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005; 23: 4975-9